UroGen Pharma Ltd [URGN] stock prices are up 1.78% to $19.4 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The URGN shares have gain 2.37% over the last week, with a monthly amount glided 49.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on June 16, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $50 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on May 22, 2025. On April 16, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $23 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on August 22, 2024. Jefferies downgraded its rating to Hold for this stock on February 08, 2023, and downed its price target to $10. In a note dated April 27, 2022, Berenberg initiated an Buy rating and provided a target price of $20 on this stock.
The stock price of UroGen Pharma Ltd [URGN] has been fluctuating between $3.42 and $19.74 over the past year. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $19.4 at the most recent close of the market. An investor can expect a potential return of 21.13% based on the average URGN price forecast.
Analyzing the URGN fundamentals
The UroGen Pharma Ltd [NASDAQ:URGN] reported sales of 91.87M for trailing twelve months, representing a surge of 7.84%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -974.87 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.72 points at the first support level, and at 18.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.83, and for the 2nd resistance point, it is at 20.26.
Ratios To Look Out For
It’s worth pointing out that UroGen Pharma Ltd [NASDAQ:URGN]’s Current Ratio is 5.65. As well, the Quick Ratio is 5.47, while the Cash Ratio is 2.48. Considering the valuation of this stock, the price to sales ratio is 9.76.
Transactions by insiders
Recent insider trading involved Smith Jason Drew, General Counsel, that happened on Jul 28 ’25 when 7522.0 shares were sold. Chief Medical Officer, Schoenberg Mark completed a deal on Jul 28 ’25 to sell 5149.0 shares. Meanwhile, Officer Schoenberg Mark bought 5149.0 shares on Jul 28 ’25.
